# Infliximab treatment for Cronkhite-Canada syndrome in pregnancy: A case report

## TL;DR

A pregnant woman with Cronkhite-Canada syndrome was successfully treated with infliximab, resulting in a healthy baby and no disease flare-ups.

## Contribution

First documented case of managing Cronkhite-Canada syndrome during pregnancy using anti-TNF-α therapy.

## Key findings

- Infliximab maintained disease control throughout pregnancy and postpartum.
- A healthy infant was delivered at 38 weeks with no CCS exacerbation.
- Anti-TNFα therapy may improve outcomes for pregnant patients with CCS.

## Abstract

Cronkhite-Canada syndrome (CCS) is a rare nonhereditary disorder characterized by gastrointestinal polyps and protein-losing enteropathy. While an increasing number of CCS cases have been reported worldwide, no documented cases involving pregnant patients could be found. Consequently, optimal management strategies for CCS during the preconception period and pregnancy remain unclear., The present report concerns the case of a 36-year-old woman with steroid-refractory CCS stabilized with gastrointestinal surgeries and infliximab, an anti-tumor necrosis factor-α (TNF-α) agent, who became pregnant. Infliximab was continued throughout pregnancy and postpartum. Despite persistent hypoalbuminemia, sh delivered a healthy infant weighing 2518 g vaginally at 38 weeks and 2 days without CCS exacerbation. Both the patient and her infant experienced an uneventful postpartum course. This case suggests that maintaining disease control with anti-TNF-α therapy in pregnant patients with CCS may contribute to optimizing maternal and neonatal outcomes.

•First documented case of pregnancy in a patient with Cronkhite-Canada syndrome (CCS).•Infliximab maintained CCS disease control from periconception through postpartum period.•Anti-TNFα therapy may contribute to favorable maternal and neonatal outcomes in CCS.

First documented case of pregnancy in a patient with Cronkhite-Canada syndrome (CCS).

Infliximab maintained CCS disease control from periconception through postpartum period.

Anti-TNFα therapy may contribute to favorable maternal and neonatal outcomes in CCS.